Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin Versus Heparin for Systemic Anticoagulation in ECMO
NCT03965208Phase 4Unknown
- Sponsor
- Legacy Health
- Start
- May 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bivalirudin in extracorporeal membrane oxygenation complication (2 arms), sponsored by Legacy Health. Primary endpoint: Percentage of time in the target anticoagulation range up to 12 weeks. Status: unknown.
02
Drugs
bivalirudin
03
Conditions
extracorporeal membrane oxygenation complication
Beyond the preview
Go deeper on NCT03965208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965208.